Novo, Nordisks

Novo Nordisk's Australian Tablet Lead Looks Set to Slip as Lilly Lines Up Faster Launch

Published on 11/17/2026 at 13:02 | Editorial boerse-global.de
Australia's TGA cleared Lilly's Foundayo for weight management, expected within days, while Novo's Wegovy tablet supplies aren't slated until end of 2026.
Novo, Nordisks, Australian, Tablet, Lead, Looks, Set, Slip, Lilly, Lines Illustration mit AI erstellt.

Novo Nordisk holds the approval, but Lilly may get to the pharmacy shelf first. Australia's TGA has cleared Lilly's Foundayo for weight management, Nine reported yesterday, just weeks after Novo's Wegovy tablet won its own green light in early November. The catch for investors sits in the delivery dates: Foundayo is expected to be available within days, while Wegovy supplies are not slated to arrive until the end of 2026.

That gap shifts the focus from regulatory milestones to commercial execution. Foundayo was also approved in Australia for type 2 diabetes, with a reported monthly price of AUD 250–370 depending on dose. The Wegovy tablet carries a recommended monthly price of AUD 260–395, according to the Australian Financial Review — a list recommendation rather than a statement of realised sales.

Self-Payers Bear the Cost, So Price and Convenience Decide

Reimbursement shapes the contest. Australia's PBS generally does not subsidise GLP-1 medicines prescribed solely for weight loss, and both tablets are prescription-only. With patients paying out of pocket, price becomes a core competitive lever. Dosing routine differs too: Foundayo can be taken at any time of day, whereas the Wegovy tablet must be taken in the morning on an empty stomach. Neither detail predicts commercial success on its own, but both belong to the concrete features separating the two products.

Beyond Australia, Novo is waiting on another regulatory call. It expects the US FDA to rule on CagriSema for weight control in the fourth quarter of 2026, with a US launch planned for early 2027, subject to approval. The drug, designed as a successor to Wegovy, combines GLP-1 with amylin.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Bone-Health Data and Real-World Food Noise

Clinical context for that amylin programme arrived yesterday, when Novo presented research on a possible link between amylin-based drug candidates and bone health during weight loss. The company stressed that the exploratory findings — spanning preclinical work and human biomarker studies — require further clinical research, and that the investigation was not designed to assess a reduction in fracture risk. The medicines involved remain in development.

On the real-world front, Novo used Saturday's ObesityWeek to present results from the SIGNAL and OCTANE studies. Injected semaglutide showed an association with lower scores for food-related mental preoccupation, known as "food noise." For oral semaglutide, three months of treatment was linked to a decline of roughly 25% in average reported scores — an observed association, the company said.

A Danish Reimbursement Win and a USD 200 Million Pledge

Access to an existing product widened in Denmark on 9 November, when Ozempic 2 mg secured conditional general reimbursement for certain adults with type 2 diabetes, per the Danish Medicines Agency. The decision, taken on 28 October, rests on a confidentially negotiated price.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

Novo also confirmed yesterday that it had executed share buybacks under the programme launched on 6 May, filing the required disclosure with the US securities regulator. And on 11 November the company committed USD 200 million to the World Diabetes Foundation for 2027–2036, aimed at diabetes prevention and care in low- and middle-income countries.

For the equity story, the distinction between product progress and actual marketing remains the thread to watch. In Australia, approval is banked; availability, pricing and access come next. On CagriSema, the FDA decision stays the gate.

Ad

Novo Nordisk Stock: New Analysis - 17 November

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

Disclaimer...
en | DK0062498333 | NOVO | boerse | 70526478 |